WanJie TianYuan Completes Nearly RMB 100 Million Series B Financing to Advance Minimally Invasive Orthopedics and Tissue Regeneration

Feb 19, 2025 18:13 CST Updated 18:13

Wanjie Medical

Orthopedic Consumables Manufacturer

Instrument Family

Medical Device Media Reporting Pioneer

Share Professional Medical Device Knowledge

Focus

Source: Wanjie Medical

Wanjie Medical Completes Nearly 100 Million Yuan in B-Round Financing, with MaiLin Capital Serving as Exclusive Financial Advisor

"Thanks to MaiLin Capital for their assistance in this round of financing. In the current highly uncertain capital market environment, they helped Wanjie Medical successfully complete this round of financing and provided comprehensive support to the company in many aspects such as capital planning, government relations, and key customers. Wishing MaiLin Capital further success!"

——Founder of Wanjie Medical, Ms. Zhang Mei

Recently, Beijing Wanjie Medical Device Co., Ltd. (hereinafter referred to as "Wanjie Medical") announced the successful completionNearly 100 Million Yuan in Series B Financing.This round of financing was led byChina Science InvestmentInvestment by its funds,Pulse Forest CapitalActing as the exclusive financial advisor. Since its establishment, Wanjie Medical has received continuous support from professional investment institutions such as Yilian Capital. This round of financing will mainly be used for research and development in the orthopedic minimally invasive and tissue regeneration industries, accelerating product commercialization, and advancing the iterative development of mature products.

Wanjie Medical was founded in 2006, with its headquarters located in the Zhongguancun Medical Device Park, known as China's Pharmaceutical Valley. It has served as the vice chairman unit of the China Sports Medicine Industry-University-Research Innovation Alliance, and has been approved as a postdoctoral research workstation. The company has been recognized as a Beijing "Specialized, Refined, Unique, and Innovative Little Giant" enterprise, a Beijing Patent Pilot Unit, and one of the top 20 enterprises in comprehensive R&D strength in China's medical device industry.

Wanjie Medical focuses on minimally invasive orthopedics (sports medicine, spinal minimally invasive, joint surgery), tissue repair and regeneration, and medical aesthetics. Its product portfolio includes a range of advanced devices in emerging orthopedic fields such as 4K medical endoscopic camera systems, arthroscopes, percutaneous endoscopes, plasma surgical equipment, medical pulse lavage suction systems, meniscus suture systems, adjustable titanium plate systems with loops, suture anchors, platelet-rich plasma preparation kits, and medical bone cement. With a comprehensive product matrix, Wanjie Medical has gained recognition from numerous clinical practitioners.

As of now, Wanjie Medical has applied for more than 60 patents and obtained 46 medical device registration certificates.Its core products have achieved full coverage across all 32 provinces in China, with over 2,000 supply partners, entering more than 2,200 hospitals, of which the coverage rate in tertiary hospitals exceeds 80%. It has established research partnerships with institutions such as Peking University Third Hospital, PLA General Hospital, and Shanghai Sixth People's Hospital.

Dedicated Research, Accumulating Strength for Future Breakthroughs. In the context of China's nationwide centralized procurement of medical devices organized by the state, Wanjie Medical continues to forge ahead with determination, embracing challenges without limits. Committed to innovation as its core driving force, the company collaborates deeply with numerous research institutions, medical organizations, and renowned experts within China. By gathering professional talents from various fields and relying on an advanced production system, Wanjie Medical has established a unique industry-academia-research-clinical innovation system. Through this collaborative platform, the company stays at the forefront of industry innovation trends, promotes the transformation of scientific achievements into practical applications, and continuously launches technologically advanced medical consumables, equipment, and tools, accelerating product upgrades and iterations.

Wanjie Medical's "Artificial Ligament" and "Articular Cartilage Repair Scaffold" projects have passedSpecial Review for Innovative Medical DevicesChannel, in which the articular cartilage repair scaffold was awarded the "China Invention Patent Gold Award"，filling the gap in China's cartilage repair field. The "bioactive glass artificial bone" project has entered the MIIT's biomedical materials innovation task."Open ChallengeList, contributing to China's biomedicine materials technology breakthrough and self-reliance in science and technology.

Wanjie Medical's management team has extensive experience in research and development and commercialization in the orthopedic consumables field. Ms. Zhang Mei, the founder of Wanjie Medical, has over 20 years of deep involvement in the medical device R&D sector, with remarkable insights particularly in sports medicine, orthopedic new materials, and tissue repair, serving as the spiritual pillar for the company’s continuous growth. The core executives of the company all hail from well-known medical device enterprises in China, possessing profound expertise and abundant management experience in product development, clinical affairs management, and market expansion.

In the upcoming era of medical innovation, Wanjie Medical will continue to focus on the fields of minimally invasive orthopedics and tissue regeneration, striving to provide patients with comprehensive solutions for minimally invasive orthopedic surgeries, promoting the substitution of domestically produced medical devices, and building a high-quality Chinese brand.

Ms. Zhang Mei, founder of Wanjie Medical, stated

Against the backdrop of severe challenges in the current medical device industry financing environment, the company has always stayed true to its original mission, firmly implementing an innovation-driven development strategy. Focusing on in-depth research in the fields of tissue repair and minimally invasive orthopedics, it continuously launches groundbreaking innovative products. In this process,The company would like to express its special thanks to the long-term support from the old shareholder Yilian Capital and the trust given by the new shareholder Guoke Investment.Looking ahead, our company will continue to rely on its excellent R&D capabilities and innovation power, as always, commit to creating more brilliant achievements, generate greater value for shareholders, and contribute more to the development of the industry.

Liu Chunguang, Investment Director of Guoke Investment, said

The medical field is an evergreen track for investment. Under the trend of aging, the incidence of orthopedic diseases such as spinal and joint conditions is increasing. With innovative solutions like vertebral body augmentation and cartilage repair gradually maturing, minimally invasive orthopedic intervention products will embrace rapid market growth opportunities. Wanjie Medical boasts a rich product portfolio, covering multiple areas including sports medicine, minimally invasive spine, biomaterials, and orthopedic consumables. The company’s team demonstrates foresight and strong innovation capabilities in product development and pipeline planning, providing comprehensive solutions for minimally invasive orthopedic treatments to better meet clinical needs. We are optimistic about Wanjie Medical's development prospects and will support the company in becoming a leader in the fields of minimally invasive orthopedics and tissue regeneration.

Xu Luobin, Managing Partner of Yilian Capital, said

We are very pleased to see Wanjie Medical successfully complete its financing. As early investors, we have witnessed the company grow from a startup to become a leader in the fields of minimally invasive orthopedics and tissue regeneration. The company's continuous investment in R&D and market expansion has earned widespread recognition. Especially under the current industry challenges, Wanjie Medical has adhered to innovation-driven growth, demonstrating strong resilience and execution capabilities. We believe that after completing this new round of financing, the company will accelerate product development and market layout, providing higher quality solutions for patients worldwide. Yilian Capital will continue to support the development of Wanjie Medical and looks forward to jointly creating an even more brilliant future.

Zhu Peilin, founding partner of MaiLin Capital, stated

China's orthopedic market shows steady growth. As China gradually enters a moderately aging society, the incidence of orthopedic conditions has also increased. Meanwhile, improvements in people's payment capabilities and health awareness are expected to enhance the penetration rate of orthopedic surgeries, further boosting the growth of the orthopedic market. Wanjie Medical has extensive experience in orthopedic research and sales, with leading competitive products, comprehensive layouts in tissue regeneration and sports medicine product lines, and expansion into the spinal minimally invasive field. The company demonstrates strong continuous R&D capabilities, with two innovative products — "artificial ligament" and "joint cartilage repair scaffold" — featuring high technical barriers and broad application prospects. We look forward to the company entering a phase of rapid development and continuing to receive support throughout its growth journey.

END

Olympus: Comprehensive Business Restructuring

China's Medical Consumables in 2024: First Registration with 95% Localization Rate

China's Endoscope Leader Completes Cross-Border Acquisition

China's Medical Devices in 2024: Endoscopes Take the Lead in First-Time Registrations

Wearable Cardioverter Defibrillator Unicorn to IPO

Over 160 Million Yuan: Who Won the Five Major Ultrasound Procurement Projects?

Intuitive Surgical Founder Joins Ophthalmic Surgery Robotics Company

United Imaging Healthcare: World's First Silicon Carbide MRI Unveiled, Energy Consumption Drops by 57%!

Just now, the U.S. healthcare system cuts 5,200 jobs

Instrument Family: Top 10 Medical Device Innovations of 2025

BusinessBusiness cooperation email: qxzj@landianyiliao.com